{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:48:47Z","timestamp":1784234927788,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04806-4","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T08:31:47Z","timestamp":1755937907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase"],"prefix":"10.1007","volume":"95","author":[{"given":"Sherwin K. B.","family":"Sy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Yong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohinoor","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Grosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"Supplement 1","key":"4806_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2023-182792","volume":"142","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Br\u00fcmmendorf TH, La Ros\u00e9e P, Heim D, Krause SW, le Coutre PJB (2023) Treatment free remission after nilotinib plus peg-interferon alpha induction and peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients; the Tiger trial. Blood 142(Supplement 1):446. https:\/\/doi.org\/10.1182\/blood-2023-182792","journal-title":"Blood"},{"issue":"1","key":"4806_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F (2021) Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol 14(1):44. https:\/\/doi.org\/10.1186\/s13045-021-01055-9","journal-title":"J Hematol Oncol"},{"key":"4806_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW (2020) The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res 98:106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458","journal-title":"Leuk Res"},{"issue":"11","key":"4806_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","volume":"63","author":"M Hoch","year":"2024","unstructured":"Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, Fu Y, Sy SKB, Obourn V, Chakraborty A, Hourcade-Potelleret F (2024) Clinical pharmacology of asciminib: a review. Clin Pharmacokinet 63(11):1513\u20131528. https:\/\/doi.org\/10.1007\/s40262-024-01428-6","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4806_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garcia-Gutierrez V, Kapoor S, Allepuz A, Quenet S, Bedoucha V, Mauro MJ (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617\u2013626. https:\/\/doi.org\/10.1038\/s41375-023-01829-9","journal-title":"Leukemia"},{"issue":"10","key":"4806_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP, for the ASC4FIRST Investigators (2024) Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med 391(10):885\u2013898. https:\/\/doi.org\/10.1056\/NEJMoa2400858","journal-title":"N Engl J Med"},{"issue":"21","key":"4806_CR7","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bedoucha V, Hochhaus A (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031\u20132041. https:\/\/doi.org\/10.1182\/blood.2020009984","journal-title":"Blood"},{"issue":"5","key":"4806_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gomez-Garcia de Soria V, le Coutre P, Mahon FX, Janssen J, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F (2023) Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior tkis: 4-year phase 1 safety and efficacy results. Leukemia 37(5):1048\u20131059. https:\/\/doi.org\/10.1038\/s41375-023-01860-w","journal-title":"Leukemia"},{"issue":"10","key":"4806_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY (2022) Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet 61(10):1393\u20131403. https:\/\/doi.org\/10.1007\/s40262-022-01148-9","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4806_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-025-04755-y","volume":"95","author":"C Darstein","year":"2025","unstructured":"Darstein C, Yoon D, Yang Y, Kapoor S, Dasgupta K, Wu S, Kawakita Y, Hoch M, Grosch K, Sy SKB (2025) Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 95(1):39. https:\/\/doi.org\/10.1007\/s00280-025-04755-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4806_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/bcp.16381","volume":"91","author":"SKB Sy","year":"2025","unstructured":"Sy SKB, Yoon DY, Darstein C, Yang Y, Dasgupta K, Kapoor S, Hoch M, Grosch K (2025) Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model. Br J Clin Pharmacol 91(5):1419\u20131430. https:\/\/doi.org\/10.1111\/bcp.16381","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"4806_CR12","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423\u20131432. https:\/\/doi.org\/10.1056\/NEJMoa030513","journal-title":"N Engl J Med"},{"issue":"5","key":"4806_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/cpt.2699","volume":"112","author":"FP Combes","year":"2022","unstructured":"Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB (2022) Exposure-efficacy analysis of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther 112(5):1040\u20131050. https:\/\/doi.org\/10.1002\/cpt.2699","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4806_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","volume":"37","author":"D Rea","year":"2023","unstructured":"Rea D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D\u2019Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A (2023) Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia 37(5):1060\u20131067. https:\/\/doi.org\/10.1038\/s41375-023-01888-y","journal-title":"Leukemia"},{"issue":"5","key":"4806_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cpdd.1213","volume":"12","author":"M Hoch","year":"2023","unstructured":"Hoch M, Bebrevska L, Singh N, Hourcade-Potelleret F (2023) Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants. Clin Pharmacol Drug Dev 12(5):484\u2013492. https:\/\/doi.org\/10.1002\/cpdd.1213","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"4806_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40262-024-01411-1","volume":"63","author":"FP Combes","year":"2024","unstructured":"Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, Hoch M, Ho YY (2024) Dose justification for asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet 63(9):1301\u20131312. https:\/\/doi.org\/10.1007\/s40262-024-01411-1","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"4806_CR17","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-24-1086","volume":"30","author":"GE Pamuk","year":"2024","unstructured":"Pamuk GE, Chow ECY, Ionan AC, Chen H, Lee SL, Hsu V, Grimstein M, Zheng N, Sun J, Charlab R, Gehrke BJ, Vallejo J, Ehrlich LA, de Claro RA, Theoret MR (2024) FDA approval summary: asciminib for Ph\u2009+\u2009CML in chronic phase treated with two or more tyrosine kinase inhibitors and for the T315I mutation. Clin Cancer Res 30(19):4266\u20134271. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1086","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4806_CR18","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen J, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326. https:\/\/doi.org\/10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"issue":"14","key":"4806_CR19","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on Imatinib. J Clin Oncol 28(14):2381\u20132388. https:\/\/doi.org\/10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"},{"issue":"14","key":"4806_CR20","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and Imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733\u20133736. https:\/\/doi.org\/10.1182\/blood-2010-10-309807","journal-title":"Blood"},{"issue":"6","key":"4806_CR21","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3904\/kjim.2021.158","volume":"36","author":"Y Kim","year":"2021","unstructured":"Kim Y, Go TH, Jang J, Lee JB, Lim ST, Shim KY, Lee JI, Kong JH (2021) Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. Korean J Intern Med 36(6):1450\u20131458. https:\/\/doi.org\/10.3904\/kjim.2021.158","journal-title":"Korean J Intern Med"},{"issue":"1","key":"4806_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11096-013-9876-7","volume":"36","author":"TC Chen","year":"2014","unstructured":"Chen TC, Chen LC, Huang YB, Chang CS (2014) Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharm 36(1):172\u2013181. https:\/\/doi.org\/10.1007\/s11096-013-9876-7","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"4806_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/17474086.2021.1886918","volume":"14","author":"F Efficace","year":"2021","unstructured":"Efficace F, Vignetti M, Sparano F, Scalzulli E, Breccia M (2021) Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Expert Rev Hematol 14(3):293\u2013302. https:\/\/doi.org\/10.1080\/17474086.2021.1886918","journal-title":"Expert Rev Hematol"},{"issue":"36","key":"4806_CR24","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","volume":"34","author":"AN Winn","year":"2016","unstructured":"Winn AN, Keating NL, Dusetzina SB (2016) Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol 34(36):4323\u20134328. https:\/\/doi.org\/10.1200\/JCO.2016.67.4184","journal-title":"J Clin Oncol"},{"issue":"2","key":"4806_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","volume":"193","author":"S Claudiani","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C, Dominy AJI, Foskett K, Foroni P, Khorashad L, Milojkovic J D (2021) TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol 193(2):346\u2013355. https:\/\/doi.org\/10.1111\/bjh.17286","journal-title":"Br J Haematol"},{"issue":"7","key":"4806_CR26","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","volume":"38","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen J, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D (2024) Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u2265 1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38(7):1522\u20131533. https:\/\/doi.org\/10.1038\/s41375-024-02278-8","journal-title":"Leukemia"},{"issue":"38","key":"4806_CR27","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1080\/14796694.2024.2402680","volume":"20","author":"EL Atallah","year":"2024","unstructured":"Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE (2024) Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE phase II trial. Future Oncol 20(38):3065\u20133075. https:\/\/doi.org\/10.1080\/14796694.2024.2402680","journal-title":"Future Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04806-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T08:31:48Z","timestamp":1755937908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04806-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04806-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SKBS, CD, DYY, KD, SK, SW, YK, MH, KG are employees of Novartis. YY was an employee of Novartis. SKBS, CD, KD, SK, MH, KG own Novartis shares.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}